Please assess the completion status of the following clinical trial:

Trial Title: TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing to start or continue oral contraceptive therapy, specifically ethinylestradiol and norethindrone, for the duration of the study~* Consent to a method of birth control in addition to the OC trial medication~* Non-smoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to screening~* Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, extremes included~* Healthy on the basis of a physical examination, medical history, electrocardiogram, vital signs and the results of blood biochemistry and hematology tests and a urinalysis carried out at screening.~Exclusion Criteria:~* The most important eligibility criteria are: Not pregnant or breastfeeding~* Not postmenopausal~* No positive HIV test~* No alcohol or barbiturate, amphetamine, recreational or narcotic drug use~* No hepatitis A, B or C infection~* No currently active gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory or infectious disease~* No history of significant skin disease~* No previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the medication administered in this trial (i.e. TMC278, Ovysmen®)~* No clinical significant abnormal finding in the gynaecological examination~* No currently active gynaecological disorders~* No major medical condition that would preclude the safe administration of oral contraceptive therapy~* No participation in an investigational drug trial within 60 days prior to the start of the first OC cycle

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).